Product
CDX-527
1 clinical trial
14 indications
Indication
Lung CancerIndication
Breast CancerIndication
Stomach CancerIndication
Renal Cell CarcinomaIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaIndication
Fallopian tube cancerIndication
CholangiocarcinomaIndication
Bladder Urothelial CarcinomaIndication
MSI-H Colorectal CancerIndication
Esophageal cancerIndication
Liver CancerIndication
Head and Neck CancerIndication
Solid TumorsClinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2023-04-06